Protective role of berberine and Coptischinensis extract on T2MD rats and associated islet Rin‑5f cells

Jiang,Yu‑Yu; Cui,Han‑Ming; Wang,Jia‑Long; Liu,Hui; Dang,Meng‑Meng; Zhang,Qiu‑Yan; Yang,Fang; Kou,Jian‑Tao; Tong,Xiao‑Lin

doi:10.3892/mmr.2017.7467

Protective role of berberine and Coptischinensis extract on T2MD rats and associated islet Rin‑5f cells

Authors:
- Yu‑Yu Jiang
- Han‑Ming Cui
- Jia‑Long Wang
- Hui Liu
- Meng‑Meng Dang
- Qiu‑Yan Zhang
- Fang Yang
- Jian‑Tao Kou
- Xiao‑Lin Tong
View Affiliations

Affiliations: The Management of Chronic Disease and Rehabilitation Department, Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China, Department of Chinese Traditional Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China, Department of Traditional Chinese Medicine, College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China, Department of Agriculture and Life Sciences, Ankang University, Ankang, Shaanxi 725000, P.R. China, Department of Orthopedics, Hebei Wen'an Hospital, Langfang, Hebei 065800, P.R. China, Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China
Published online on: September 12, 2017 https://doi.org/10.3892/mmr.2017.7467
Pages: 6981-6991

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the different effects of berberine (Ber) and Coptischinensis extract (CCE) on a rat model of type 2 diabetes mellitus (T2DM), and the islet Rin‑5f cell line was used to examine the differences between Ber and CCE and the underlying mechanisms. CCE was extracted and purified prior to analysis. Male Sprague‑Dawley rats were provided with a high‑fat diet to induce insulin resistance prior to injecting with streptozotocinto establish the T2DM model, the T2DM rats were treated with Ber and CCE, and blood samples and pancreatic tissues were obtained and compared to examine T2DM metabolic syndromes among the groups of rats, which included healthy rats, model rats, and model rats treated with Ber and CCE at different doses between 0 and 8 weeks. The protective effects of Ber and CCE on the Rin‑5f islet cell line were also evaluated. The effects on Rin‑5f cell proliferation and cell cycle, glucose‑stimulated insulin release test (GSIS), the anti‑apoptotic effects caused by fat induction, and protein expression levels of poly ADP‑ribose polymerase (PARP‑1) were evaluated. The results showed that the content of the prepared CCE was 96.07% for five alkaloids. When it was used for treatment of the T2DM rats, compared with Ber, metformin and rosiglitazone, the fasting blood glucose, glucosylated serum protein (GSP) and glucose infusion rate indicesin the fasting rats were ameliorated, compared with those in the T2MD rats, with no significant differences between treatment with Ber or CCE and metformin or rosiglitazone. The indices of mean optical density and fasting β‑cell function index (FBCI) were different following treatment with Ber and CCE, compared with those in the model rats, which may have stimulated the pancreatic secretion of insulin. When Ber and CCE were used to examine the protective effects on Rin‑5F cells, it was found that the Rin‑5f cell GSIS, cell cycle, lipotoxic islet cell proliferation and protein expression of PARP‑1 were altered and improved, which may have protected pancreatic islet β‑cells by improving islet β‑cell proliferation and the protein expression of PARP‑1. CCE and Ber exerted similar effects when used for the treatment of T2MD rats, and may have stimulated the pancreatic secretion of insulin through the protective effect on islet β‑cells via improving islet β‑cell proliferation and the protein expression of PARP‑1.

View Figures

View References

1	Mao T, Yan Q, Zhou F and Shen YZ: Isolation and identification of berberine from cell cultures of Coptis chinensis. Chin J Biotechnol. 13:193–199. 1997.PubMed/NCBI
2	Ríos JL, Francini F and Schinella GR: Natural products for the treatment of Type 2 diabetes mellitus. Planta Med. 81:975–994. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sun SF, Zhao TT, Zhang HJ, Huang XR, Zhang WK, Zhang L, Yan MH, Dong X, Wang H, Wen YM, et al: Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 42:662–670. 2015. View Article : Google Scholar : PubMed/NCBI
4	Di Pierro F, Bellone I, Rapacioli G and Putignano P: Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes. 8:89–96. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chang W, Chen L and Hatch GM: Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol. 93:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J and Sun G: Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 161:69–81. 2015. View Article : Google Scholar : PubMed/NCBI
7	Dong Y, Chen YT, Yang YX, Zhou XJ, Dai SJ, Tong JF, Shou D and Li C: Metabolomics study of type 2 diabetes mellitus and the antidiabetic effect of berberine in zucker diabetic fatty rats using Uplc-ESI-Hdms. Phytother Res. 30:823–828. 2016. View Article : Google Scholar : PubMed/NCBI
8	Yi Q, He XE, Luo KF, Zhang GS, Liu YH, Xue Q, Hou N, Chen WL and Luo JD: Protection of long-term treatment with huang-lian-jie-du-tang on vascular endothelium in rats with type 2 diabetes mellitus. Curr Ther Res Clin Exp. 73:174–185. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li CB, Li XX, Chen YG, Gao HQ, Bu PL, Zhang Y and Ji XP: Huang-lian-jie-du-tang protects rats from cardiac damages induced by metabolic disorder by improving inflammation-mediated insulin resistance. PLoS One. 8:e675302013. View Article : Google Scholar : PubMed/NCBI
10	Wu JS, Shi R, Lu X, Ma YM and Cheng NN: Combination of active components of Xiexin decoction ameliorates renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad pathways in db/db diabetic mice. PLoS One. 10:e01226612015. View Article : Google Scholar : PubMed/NCBI
11	Yang Z, Wang L, Zhang F and Li Z: Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches. BMC Complement Altern Med. 15:2722015. View Article : Google Scholar : PubMed/NCBI
12	Chang YX, Ge AH, Donnapee S, Li J, Bai Y, Liu J, He J, Yang X, Song LJ, Zhang BL and Gao XM: The multi-targets integrated fingerprinting for screening anti-diabetic compounds from a Chinese medicine Jinqi Jiangtang Tablet. J Ethnopharmacol. 164:210–222. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zarei A, Changizi-Ashtiyani S, Taheri S and Ramezani M: A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed. 5:485–497. 2015.PubMed/NCBI
14	Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ and Tong XL: Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol. 2015:9057492015. View Article : Google Scholar : PubMed/NCBI
15	Pang B, Yu XT, Zhou Q, Zhao TY, Wang H, Gu CJ and Tong XL: Effect of rhizoma coptidis (Huang Lian) on treating diabetes mellitus. Evid Based Complement Alternat Med. 2015:9214162015. View Article : Google Scholar : PubMed/NCBI
16	Li F, Zhao YB, Wang DK, Zou X, Fang K and Wang KF: Berberine relieves insulin resistance via the cholinergic anti-inflammatory pathway in HepG2 cells. J Huazhong Univ Sci Technolog Med Sci. 36:1–69. 2016. View Article : Google Scholar : PubMed/NCBI
17	Geng FH, Li GH, Zhang X, Zhang P, Dong MQ, Zhao ZJ, Zhang Y, Dong L and Gao F: Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signaling in diabetic rats. Br J Pharmacol. 173:1569–1579. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lu L, Zhijian H, Lei L, Wenchuan C and Zhimin Z: Berberine in combination with insulin has additive effects on titanium implants osseointegration in diabetes mellitus rats. Evid Based Complement Alternat Med. 2015:8242592015. View Article : Google Scholar : PubMed/NCBI
19	Yu Y, Hao G, Zhang Q, Hua W, Wang M, Zhou W, Zong S, Huang M and Wen X: Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol. 97:173–177. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhou J, Du X, Long M, Zhang Z, Zhou S, Zhou J and Qian G: Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats. Eur J Pharmacol. 774:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
21	Tang LQ, Ni WJ, Cai M, Ding HH, Liu S and Zhang ST: The renoprotective effects of berberine and its potential impact on the expression of β-arrestins and ICAM-1/VCAM-1 in streptozocin induced-diabetic nephropathy rats. J Diabetes. November 3–2015.(Epub ahead of print).
22	Friedemann T, Schumacher U, Tao Y, Leung AK and Schröder S: Neuroprotective activity of coptisine from coptis Chinensis (Franch). Evid Based Complement Alternat Med. 2015:8273082015. View Article : Google Scholar : PubMed/NCBI
23	Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X and Zhao L: Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 5:144052015. View Article : Google Scholar : PubMed/NCBI
24	Xie W, Gu D, Li J, Cui K and Zhang Y: Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 6:e245202011. View Article : Google Scholar : PubMed/NCBI
25	Wu X, Li Y, Wang Q, Li W and Feng Y: Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 1007:110–120. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chang W, Li K, Guan F, Yao F, Yu Y, Zhang M, Hatch GM and Chen L: Berberine pretreatment confers cardioprotection against ischemia-reperfusion injury in a rat model of type 2 diabetes. J Cardiovasc Pharmacol Ther. 21:486–494. 2016. View Article : Google Scholar : PubMed/NCBI
27	Dai P, Wang J, Lin L, Zhang Y and Wang Z: Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. Exp Ther Med. 10:869–876. 2015. View Article : Google Scholar : PubMed/NCBI
28	Chang W, Zhang M, Meng Z, Yu Y, Yao F, Hatch GM and Chen L: Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5′-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. Eur J Pharmacol. 769:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
29	Jiang SJ, Dong H, Li JB, Xu LJ, Zou X, Wang KF, Lu FE and Yi P: Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol. 21:7777–7785. 2015. View Article : Google Scholar : PubMed/NCBI
30	Jhong CH, Riyaphan J, Lin SH, Chia YC and Weng CF: Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico. Biofactors. 41:242–251. 2015. View Article : Google Scholar : PubMed/NCBI
31	Chang W, Chen L and Hatch GM: Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes. Biochim Biophys Acta. 1864:352–362. 2016. View Article : Google Scholar
32	Pirillo A and Catapano AL: Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis. 243:449–461. 2015. View Article : Google Scholar : PubMed/NCBI
33	Xue M, Zhang L, Yang MX, Zhang W, Li XM, Ou ZM, Li ZP, Liu SH, Li XJ and Yang SY: Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int J Nanomedicine. 10:5049–5057. 2015. View Article : Google Scholar : PubMed/NCBI
34	Zhang Y, Chang X, Song X, Chen C, Chen H, Lu Z, Gao X and Lu D: Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat. Int J Clin Exp Med. 8:7535–7543. 2015.PubMed/NCBI
35	Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X and Zhou L: Berberine suppresses adipocyte differentiation via decreasing Creb transcriptional activity. PLoS One. 10:e01256672015. View Article : Google Scholar : PubMed/NCBI
36	Wang Z, Wu J, Zhou Q, Wang Y and Chen T: Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice. Evid Based Complement Alternat Med 2015. 2397492015.
37	Liu C, Wang Z, Song Y, Wu D, Zheng X, Li P, Jin J, Xu N and Li L: Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. Biomed Res Int. 2015:3138082015.PubMed/NCBI
38	Cui E, Zhi X, Chen Y, Gao Y, Fan Y, Zhang W, Ma W, Hou W, Guo C and Song X: Coptis chinensis and myrobalan (Terminalia chebula) can synergistically inhibit inflammatory response in vitro and in vivo. Evid Based Complement Alternat Med. 2014:5101572014. View Article : Google Scholar : PubMed/NCBI
39	Wang O, Cai K, Pang S, Wang T, Qi D, Zhu Q, Ni Z and Le Y: Mechanisms of glucose-induced expression of pancreatic-derived factor in pancreatic beta-cells. Endocrinology. 149:672–680. 2008. View Article : Google Scholar : PubMed/NCBI
40	Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A and DeFronzo RA: Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 292:E871–E883. 2007. View Article : Google Scholar : PubMed/NCBI
41	Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, et al: Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA. 106:13992–13997. 2009; View Article : Google Scholar : PubMed/NCBI
42	Andreone T, Meares GP, Hughes KJ, Hansen PA and Corbett JA: Cytokine-mediated β-cell damage in PARP-1-deficient islets. Am J Physiol Endocrinol Metab. 303:E172–E179. 2012. View Article : Google Scholar : PubMed/NCBI
43	Radzi SF Muhd, Rückert C, Sam SS, Teoh BT, Jee PF, Phoon WH, Abubakar S and Zandi K: Detection of Langat virus by TaqMan real-time one-step qRT-PCR method. Sci Rep. 5:140072015. View Article : Google Scholar : PubMed/NCBI
44	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI